| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
| ln Vitro |
Compound 22 (UZH2), with an EC50 of 0.85 μM, dose-dependently stabilizes METTL3 in MOLM-13 cells at 54°C for 1 hour at concentrations of 0–25 μM [1]. MOLM-13 and PC-3 are decreased by UZH2 (16 h). In cells, the EC50 and m6A/A ratio of polyadenylated RNA are 0.7 μM and 2.5 μM, respectively [1].
|
|---|---|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MOLM-13 Cell Tested Concentrations: 0-25 μM Incubation Duration: 1h Experimental Results: Stabilizes METTL3 in a dose-dependent manner at 54 °C. |
| References |
| Molecular Formula |
C27H37F2N7O
|
|---|---|
| Molecular Weight |
513.625792264938
|
| Exact Mass |
513.302
|
| CAS # |
2756566-45-5
|
| PubChem CID |
156587343
|
| Appearance |
White to off-white solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
37
|
| Complexity |
783
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1CN(C2C=C(F)C(CN3CCC(C)(C)CC3)=CC=2F)CC2(CCN(C3=NC=NC(NC)=C3)CC2)N1
|
| InChi Key |
GYWOVBUGFWWSJR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H37F2N7O/c1-26(2)4-8-34(9-5-26)15-19-12-21(29)22(13-20(19)28)36-16-25(37)33-27(17-36)6-10-35(11-7-27)24-14-23(30-3)31-18-32-24/h12-14,18H,4-11,15-17H2,1-3H3,(H,33,37)(H,30,31,32)
|
| Chemical Name |
4-[4-[(4,4-dimethylpiperidin-1-yl)methyl]-2,5-difluorophenyl]-9-[6-(methylamino)pyrimidin-4-yl]-1,4,9-triazaspiro[5.5]undecan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~97.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9469 mL | 9.7346 mL | 19.4693 mL | |
| 5 mM | 0.3894 mL | 1.9469 mL | 3.8939 mL | |
| 10 mM | 0.1947 mL | 0.9735 mL | 1.9469 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
